Movement Disorders Induced by Antipsychotic Drugs: Implications of the CATIE Schizophrenia Trial

Neurologic Clinics

Volumn 29, Issue 1, 2011, Pages 127-148

  Caroff, Stanley N ^a,b   Hurford, Irene ^a,b   Lybrand, Janice ^a   Campbell, E Cabrina ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Akathisia; Antipsychotic drugs; Catatonia; Dystonia; Neuroleptic malignant syndrome; Parkinsonism; Schizophrenia; Tardive dyskinesia

Indexed keywords

AMANTADINE; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIMALARIAL AGENT; ANTIPARKINSON AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CENTRAL STIMULANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; LEVODOPA; METOCLOPRAMIDE; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERPHENAZINE; PROCHLORPERAZINE; PROPRANOLOL; QUETIAPINE; RESERPINE; RISPERIDONE; SEDATIVE AGENT; SEROTONIN ANTAGONIST; TETRABENAZINE; UNINDEXED DRUG; ZIPRASIDONE;

ADD ON THERAPY; AKATHISIA; ANTICHOLINERGIC SYNDROME; BRADYCARDIA; BRADYKINESIA; CATATONIA; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPOTENSION; INTERVENTION STUDY; LOW DRUG DOSE; META ANALYSIS (TOPIC); MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RATING SCALE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; STRIDOR; SYMPTOM; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MOVEMENT DISORDERS; SCHIZOPHRENIA;

EID: 78650251837     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2010.10.002     Document Type: Review

References (113)

1. Preskorn S.H. The evolution of antipsychotic drug therapy: reserpine, chlorpromazine, and haloperidol. J Psychiatr Pract 2007, 13(4):253-257.
2. Rifkin A. Extrapyramidal side effects: a historical perspective. J Clin Psychiatry 1987, 48(Suppl):3-6.
3. Van Putten T. Why do schizophrenic patients refuse to take their drugs?. Arch Gen Psychiatry 1975, 31:67-72.
4. Caroff S. The neuroleptic malignant syndrome. J Clin Psychiatry 1980, 41:79-83.
5. Kane J., Honigfeld G., Singer J., et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988, 45(9):789-796.
6. Arvanitis L.A., Miller B.G. Multiple fixed doses of " Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997, 42(4):233-246.
7. Potkin S.G., Saha A.R., Kujawa M.J., et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003, 60(7):681-690.
8. Tollefson G.D., Beasley C.M., Tran P.V., et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997, 154(4):457-465.
9. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994, 151(6):825-835.
10. Daniel D.G., Zimbroff D.L., Potkin S.G., et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999, 20(5):491-505.
11. Dossenbach M., Arango-Davila C., Silva Ibarra H., et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry 2005, 66(8):1021-1030.
12. Correll C.U., Leucht S., Kane J.M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004, 161(3):414-425.
13. Tenback D.E., van Harten P.N., Slooff C.J., et al. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry 2005, 66(9):1130-1133.
14. Caroff S.N., Mann S.C., Campbell E.C., et al. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002, 63(Suppl 4):12-19.
15. Tarsy D., Baldessarini R.J., Tarazi F.I. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002, 16(1):23-45.
16. Kane J.M., Woerner M., Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988, 8(4 Suppl):52S-56S.
17. Glazer W.M. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry 2000, 61(Suppl 4):21-26.
18. Glazer W.M. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000, 61(Suppl 3):16-21.
19. Leucht S., Pitschel-Walz G., Abraham D., et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999, 35(1):51-68.
20. Meltzer H.Y. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991, 17(2):263-287.
21. Davis J.M., Chen N., Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003, 60(6):553-564.
22. Geddes J., Freemantle N., Harrison P., et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000, 321(7273):1371-1376.
23. Leucht S., Wahlbeck K., Hamann J., et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003, 361(9369):1581-1589.
24. Rosenheck R., Perlick D., Bingham S., et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003, 290(20):2693-2702.
25. Hugenholtz G.W., Heerdink E.R., Stolker J.J., et al. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J Clin Psychiatry 2006, 67(6):897-903.
26. Jones P.B., Barnes T.R., Davies L., et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006, 63(10):1079-1087.
27. Correll C.U., Schenk E.M. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008, 21(2):151-156.
28. Lieberman J.A., Stroup T.S., McEvoy J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353(12):1209-1223.
29. Miller D.D., Caroff S.N., Davis S.M., et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008, 193(4):279-288.
30. Caroff S.N., Miller D.D., Rosenheck R.A. Extrapyramidal side effects. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: how does it inform practice, policy, and research? 2010, 156-172. Cambridge University Press, Cambridge (United Kingdom). T.S. Stroup, J.A. Lieberman (Eds.).
31. Satterthwaite T.D., Wolf D.H., Rosenheck R.A., et al. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry 2008, 69(12):1869-1879.
32. Tarsy D. Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis. Clin Neuropharmacol 1983, 6(Suppl 1):S9-26.
33. van Harten P.N., Hoek H.W., Kahn R.S. Acute dystonia induced by drug treatment. BMJ 1999, 319(7210):623-626.
34. Rupniak N.M., Jenner P., Marsden C.D. Acute dystonia induced by neuroleptic drugs. Psychopharmacology (Berl) 1986, 88(4):403-419.
35. Tarsy D., Simon D.K. Dystonia. N Engl J Med 2006, 355(8):818-829.
36. Marsden C.D., Quinn N.P. The dystonias. BMJ 1990, 300(6718):139-144.
37. Nemeth A.H. The genetics of primary dystonias and related disorders. Brain 2002, 125(Pt 4):695-721.
38. Keepers G.A., Casey D.E. Prediction of neuroleptic-induced dystonia. J Clin Psychopharmacol 1987, 7(5):342-345.
39. Keepers G.A., Clappison V.J., Casey D.E. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 1983, 40(10):1113-1117.
40. Simpson G.M., Lindenmayer J.P. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 1997, 17(3):194-201.
41. Arana G.W., Goff D.C., Baldessarini R.J., et al. Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. Am J Psychiatry 1988, 145(8):993-996.
42. Dayalu P., Chou K.L. Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opin Pharmacother 2008, 9(9):1451-1462.
43. Berardelli A., Rothwell J.C., Hallett M., et al. The pathophysiology of primary dystonia. Brain 1998, 121(Pt 7):1195-1212.
44. Thanvi B., Treadwell S. Drug induced parkinsonism: a common cause of parkinsonism in older people. Postgrad Med J 2009, 85(1004):322-326.
45. Bovi T, Antonini A, Ottaviani S, et al. The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism. J Neurol 2010. [Epub ahead of print].
46. Gelenberg A.J. General principles of treatment of extrapyramidal syndromes. Clin Neuropharmacol 1983, 6(Suppl 1):S52-S56.
47. Snyder S., Greenberg D., Yamamura H.I. Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry 1974, 31(1):58-61.
48. Hirsch S.R., Kissling W., Bauml J., et al. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002, 63(6):516-523.
49. Barnes T.R., McPhillips M.A. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. Br J Psychiatry Suppl 1999, 38:34-43.
50. Simpson G.M., Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970, 212:11-19.
51. Gelenberg A.J. Treating extrapyramidal reactions: some current issues. J Clin Psychiatry 1987, 48(Suppl):24-27.
52. Bras J.M., Singleton A. Genetic susceptibility in Parkinson's disease. Biochim Biophys Acta 2009, 1792(7):597-603.
53. Kane J.M., Fleischhacker W.W., Hansen L., et al. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry 2009, 70(5):627-643.
54. Bratti I.M., Kane J.M., Marder S.R. Chronic restlessness with antipsychotics. Am J Psychiatry 2007, 164(11):1648-1654.
55. Poyurovsky M. Acute antipsychotic-induced akathisia revisited. Br J Psychiatry 2010, 196(2):89-91.
56. Barnes T.R. A rating scale for drug-induced akathisia. Br J Psychiatry 1989, 154:672-676.
57. Miller C.H., Fleischhacker W.W. Managing antipsychotic-induced acute and chronic akathisia. Drug Saf 2000, 22(1):73-81.
58. Eichhammer P., Albus M., Borrmann-Hassenbach M., et al. Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia. Am J Med Genet 2000, 96(2):187-191.
59. Pichler I., Hicks A.A., Pramstaller P.P. Restless legs syndrome: an update on genetics and future perspectives. Clin Genet 2008, 73(4):297-305.
60. Ungvari G.S., Caroff S.N., Gerevich J. The catatonia conundrum: evidence of psychomotor phenomena as a symptom dimension in psychotic disorders. Schizophr Bull 2010, 36(2):231-238.
61. Jaspers K. General psychopathology 1963, Manchester University Press, Manchester (England).
62. Lopez-Canino A., Francis A. Drug-induced catatonia. Catatonia: from psychopathology to neurobiology 2004, 129-139. American Psychiatric Press, Inc, Washington, DC. S.N. Caroff, S.C. Mann, A. Francis (Eds.).
63. Gelenberg A.J., Mandel M.R. Catatonic reactions to high-potency neuroleptic drugs. Arch Gen Psychiatry 1977, 34(8):947-950.
64. White D.A., Robins A.H. An analysis of 17 catatonic patients diagnosed with neuroleptic malignant syndrome. CNS Spectr 2000, 5(7):58-65.
65. Mann S.C., Caroff S.N., Bleier H.R., et al. Lethal catatonia. Am J Psychiatry 1986, 143(11):1374-1381.
66. Gelenberg A.J. The catatonic syndrome. Lancet 1976, 1(7973):1339-1341.
67. Brenner I., Rheuban W.J. The catatonic dilemma. Am J Psychiatry 1978, 135(10):1242-1243.
68. Caroff S.N., Mann S.C., Keck P.E., et al. Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol 2000, 20(2):257-259.
69. Stubner S., Rustenbeck E., Grohmann R., et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 2004, 37(Suppl 1):S54-S64.
70. Van Den Eede F., Van Hecke J., Van Dalfsen A., et al. The use of atypical antipsychotics in the treatment of catatonia. Eur Psychiatry 2005, 20(5-6):422-429.
71. Carroll B.T., Goforth H.W., Thomas C., et al. Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes. J Neuropsychiatry Clin Neurosci 2007, 19(4):406-412.
72. Mann S.C., Caroff S.N., Fricchione G., et al. Central dopamine hypoactivity and the pathogenesis of neuroleptic malignant syndrome. Psychiatr Ann 2000, 30:363-374.
73. Stober G. Genetics. Catatonia: from psychopathology to neurobiology 2004, 173-187. American Psychiatric Press, Inc, Washington, DC. S.N. Caroff, S.C. Mann, A. Francis (Eds.).
74. Kaiser R., Konneker M., Henneken M., et al. Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia. Mol Psychiatry 2000, 5(4):418-424.
75. Kanes S.J. Animal models. Catatonia: from psychopathology to neurobiology 2004, 189-200. American Psychiatric Press, Inc, Washington, DC. S.N. Caroff, S.C. Mann, A. Francis (Eds.).
76. Strawn J.R., Keck P.E., Caroff S.N. Neuroleptic malignant syndrome. Am J Psychiatry 2007, 164(6):870-876.
77. Caroff S.N. Neuroleptic malignant syndrome. Neuroleptic malignant syndrome and related conditions 2003, 1-44. American Psychiatric Press, Inc, Washington, DC. 2nd edition. S.C. Mann, S.N. Caroff, P.E. Keck (Eds.).
78. Caroff S.N., Mann S.C., Campbell E.C., et al. Severe drug reactions. Clinical manual of psychopharmacology in the medically ill 2010, 39-77. American Psychiatric Press, Inc, Washington, DC. S.J. Ferrando, J.L. Levenson, J.A. Owen (Eds.).
79. Meltzer H.Y., Cola P.A., Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology 1996, 15(4):395-405.
80. Caroff S.N., Mann S.C., McCarthy M., et al. Acute infectious encephalitis complicated by neuroleptic malignant syndrome. J Clin Psychopharmacol 1998, 18(4):349-351.
81. Mann S.C., Boger W.P. Psychotropic drugs, summer heat and humidity, and hyperpyrexia: a danger restated. Am J Psychiatry 1978, 135(9):1097-1100.
82. Caroff S.N., Rosenberg H., Mann S.C., et al. Neuroleptic malignant syndrome in the perioperative setting. Am J Anesthesiol 2001, 28:387-393.
83. Stevens D.L. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother 2008, 42(9):1290-1297.
84. Gurrera R.J. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 1999, 156(2):169-180.
85. Kane J.M. Tardive dyskinesia: epidemiological and clinical presentation. Psychopharmacology: the fourth generation of progress 1995, 1485-1495. Raven Press, New York. F.E. Bloom, D.J. Kupfer (Eds.).
86. Casey D.E. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 1991, 4(2):109-120.
87. Burke R.E., Kang U.J., Jankovic J., et al. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord 1989, 4(2):157-175.
88. Schooler N.R., Kane J.M. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982, 39(4):486-487.
89. Guy W. Abnormal involuntary movement scale (AIMS). ECDEU assessment manual for psychopharmacology revised 1976, Alcohol, Drug Abuse and Mental Health Administration, National Institute of Mental Health, Rockville (MD), p. 534-7.
90. Casey D.E., Gerlach J. Tardive dyskinesia: what is the long-term outcome?. Tardive dyskinesia and neuroleptics: from dogma to reason 1986, 76-97. American Psychiatric Press, Inc, Washington, DC. D.E. Casey, G. Gardos (Eds.).
91. Glazer W.M., Moore D.C., Schooler N.R., et al. Tardive dyskinesia. A discontinuation study. Arch Gen Psychiatry 1984, 41(6):623-627.
92. Glazer W.M., Morgenstern H., Schooler N., et al. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry 1990, 157:585-592.
93. Soares K.V., McGrath J.J. The treatment of tardive dyskinesia-a systematic review and meta-analysis. Schizophr Res 1999, 39(1):1-16. [discussion: 17-8].
94. Gilbert P.L., Harris M.J., McAdams L.A., et al. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 1995, 52(3):173-188.
95. Caroff SN, Davis VG, Miller DD, et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. J Clin Psychiatry 2010. [Epub ahead of print].
96. Egan M.F., Apud J., Wyatt R.J. Treatment of tardive dyskinesia. Schizophr Bull 1997, 23(4):583-609.
97. Woerner M.G., Kane J.M., Lieberman J.A., et al. The prevalence of tardive dyskinesia. J Clin Psychopharmacol 1991, 11(1):34-42.
98. Chakos M.H., Alvir J.M., Woerner M.G., et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 1996, 53(4):313-319.
99. Oosthuizen P.P., Emsley R.A., Maritz J.S., et al. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 2003, 64(9):1075-1080.
100. Jeste D.V. Tardive dyskinesia in older patients. J Clin Psychiatry 2000, 61(Suppl 4):27-32.
101. Miller D.D., McEvoy J.P., Davis S.M., et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 2005, 80(1):33-43.
102. Beasley C.M., Dellva M.A., Tamura R.N., et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999, 174:23-30.
103. Jeste D.V., Lacro J.P., Bailey A., et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999, 47(6):716-719.
104. Kane J.M. Tardive dyskinesia circa 2006. Am J Psychiatry 2006, 163(8):1316-1318.
105. Kane J.M., Woerner M.G., Pollack S., et al. Does clozapine cause tardive dyskinesia?. J Clin Psychiatry 1993, 54(9):327-330.
106. Jeste D.V., Lohr J.B., Clark K., et al. Pharmacological treatments of tardive dyskinesia in the 1980s. J Clin Psychopharmacol 1988, 8(4 Suppl):38S-48S.
107. Casey D.E. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry 2000, 61(Suppl 4):5-9.
108. Miller R., Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 1993, 34(10):713-738.
109. Caroff S.N., Campbell E.C., Havey J., et al. Treatment of tardive dyskinesia with donepezil: a pilot study. J Clin Psychiatry 2001, 62(10):772-775.
110. Caroff S.N., Walker P., Campbell C., et al. Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial. J Clin Psychiatry 2007, 68(3):410-415.
111. Caroff S.N., Martine R., Kleiner-Fisman G., et al. Treatment of levodopa-induced dyskinesias with donepezil. Parkinsonism Relat Disord 2006, 12(4):261-263.
112. Tsai H.T., Caroff S.N., Miller D.D., et al. A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. Am J Med Genet B Neuropsychiatr Genet 2009, 5(153B):336-340.
113. Aberg K., Adkins D.E., Bukszar J., et al. Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 2010, 67(3):279-282.